Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2097 - Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)

Date

11 Sep 2017

Session

Poster display session

Presenters

Jayesh Desai

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

J. Desai1, M. Millward2, Y. Chao3, H. Gan4, M. Voskoboynik5, B. Markman6, A. Townsend7, V. Atkinson8, A. Zhu9, J. Song10, Q. Qi11, A. Kang12, S. Deva13

Author affiliations

  • 1 Medical Oncology, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 2 Oncology, Linear Clinical Research Ltd, 6009 - Nedlands/AU
  • 3 Oncology, Taipei Veterans General Hospital, Taipei/TW
  • 4 Austin Hospital, Olivia Newton-John Cancer Research Institute, 3084 - Heidelberg/AU
  • 5 Oncology, Nucleus Network, Melbourne/AU
  • 6 Department Of Oncology, Monash University, 3168 - Melbourne/AU
  • 7 Haematology/oncology, Queen Elizabeth Hospital, 5011 - Woodville/AU
  • 8 Department Of Medical Oncology, Princess Alexandra Hospital, 4102 - Woolloongabba/AU
  • 9 Yawkey Center For Outpatient Care, Massachusetts General Hospital, Boston/US
  • 10 Biometry, BeiGene USA, Inc, Fort Lee/US
  • 11 Clinical Research, BeiGene (Beijing) Co. Ltd, Beijing/CN
  • 12 Clinical Development, BeiGene (Beijing) Co. Ltd, Beijing/CN
  • 13 Internal Medicine, Auckland City Hospital, Auckland/NZ
More

Resources

Abstract 2097

Background

BGB-A317 is a humanized IgG4 anti-PD-1 mAb that blocks PD-L1/L2 binding to PD-1 restoring T-cell-mediated tumor inhibition. The Fc-hinge region has been engineered to preclude FcγR1-mediated binding to macrophages/myeloid-derived suppressor cells (MDSCs). Upregulation of PD-1/L1 and predominance of macrophages and MDSCs have been reported in GC and EC supporting the rationale of evaluating BGB-A317 in pts with GC or EC.

Methods

This ongoing, open-label, dose-escalation/expansion study is being conducted to evaluate the safety, tolerability and anti-tumor activity of BGB-A317 in pts with advanced solid tumors. Pts with histologically confirmed advanced GC or EC were eligible and treated with BGB-A317 at 2 mg/kg or 5 mg/kg every two weeks (Q2W) or Q3W. Adverse events (AEs) were assessed per NCI-CTCAE v4.03 and tumor assessments were performed approximately every two months via RECIST v1.1.

Results

As of 6 MAR 2017, 55 pts [median age 62 yrs (22-81)] with recurrent/refractory GC (n = 28) or EC (n = 27) were treated. Most were Caucasian (n = 36) and all pts had received ≥1 prior line of anti-cancer treatment. Median treatment duration was 51 days (5–363); 19 pts remain on study. The most common treatment-emergent AEs were fatigue (n = 11), nausea (n = 9) and dysphagia (n = 8); 46% pts experienced AEs ≥Grade (Gr) 3 but none were treatment related. One serious AE (diarrhea [Gr 2]) was considered related to treatment by investigators. Of the 47 evaluable pts, the disease control rate, defined as the proportion of pts who achieved complete or partial response (CR or PR) or stable disease (SD), is 32%. PRs have been reported in 3 pts (GC = 2; EC = 1) with duration of responses being 96, 125 and 188 days respectively, 2 pts are still on treatment; 5 initial documentations of PRs awaiting confirmation (GC, n = 2; EC, n = 3) have been reported in 12 pts with SD (GC = 5; EC = 7).

Conclusions

BGB-A317 appears to be generally well tolerated in pts with recurrent/refractory GC or EC. The preliminary safety profile and anti-tumor activity appear to be consistent with other checkpoint inhibitors and support continued exploration and development of BGB-A317 in pts with advanced GC or EC.

Clinical trial identification

NCT02407990, March 26, 2015

Legal entity responsible for the study

Beigene Ltd.

Funding

Beigene Ltd.

Disclosure

J. Desai: Honoraria: Bayer, Merck Serono, Novartis. Consulting or advisory role: Amgen, Bayer, Bionomics, Circadian Technologies, Merck Serono, Norvartis. Research funding: GlaxoSmithKline (Inst), Roche-Genentech (Inst), Ventana Medical Systems (Inst). B. Markman: Personal fees from BeiGene during the conduct of the study. V. Atkinson: Honoraria: Bristol-Myers Squibb; MSD; Novartis. Consulting/advisory role: Bristol-Myers Squibb; MSD; Novartis. Travel, accommodations, expenses: Bristol-Myers Squibb; MSD; Novartis. A. Zhu: Research Funding: Lilly (Inst). J. Song: Employee of BeiGene USA, Inc. Q. Qi: Employee of Beigene (Beijing) Co. Ltd. A. Kang: BeiGene employee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.